Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR...
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR...
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of...
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC...
Eupraxia Pharmaceuticals Strengthens Senior Management Team PR Newswire VICTORIA, BC, Oct. 2, 2024 VICTORIA...
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases PR Newswire VICTORIA...
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of...
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR...
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Aug. 7, 2024...
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility PR Newswire VICTORIA, BC, Aug...
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo PR Newswire VICTORIA, BC, July 8, 2024 VICTORIA...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders PR Newswire VICTORIA, BC, June 6, 2024...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관